Dublin, July 18, 2025 (GLOBE NEWSWIRE) -- The "Tumor Ablation Market (By Technology, Treatment Mode, Application, End-User, Regional Analysis), Company Profiles, Product Portfolio, Recent Developments, Key Trends and Market Dynamics - Global Forecast (2025 - 2032)" report has been added to ResearchAndMarkets.com's offering. The global tumor ablation market is expected to reach US$ 4.15 billion by 2032, from US$ 1.67 billion in 2024. Technological advancements to enhance accuracy, portability, and cost-effe ...

Financial Performance - AngioDynamics' total Med Device revenue grew by 62% pro forma in Q4 2025[5,9] - AngioDynamics' total Med Tech revenue grew by 220% pro forma in Q4 2025[5,9] - AngioDynamics reported pro forma Adjusted EBITDA of $34 million in Q4 2025, a $19 million improvement from Q4 FY24[5] - AngioDynamics ended the quarter with $559 million in cash and cash equivalents, up from $448 million at Feb 28, 2025[5] - AngioDynamics' total Med Tech revenue grew by 195% pro forma for FY 2025[12] - AngioDynamics' total Med Device revenue grew by 08% pro forma for FY 2025[12] Product Line Performance - Auryon sales reached $156 million in Q4 2025, a 197% year-over-year growth[16] - Total Mechanical Thrombectomy sales were $113 million in Q4 2025, a 447% year-over-year growth[5,20] - NanoKnife disposables sales grew by 55% in Q4 2025, while total NanoKnife sales decreased by 25%[5,25] Future Outlook - AngioDynamics projects full-year net sales between $305 million and $310 million for Fiscal Year 2026[27]